Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease

Levodopa-induced dyskinesia (LID) is a common motor complication in patients with Parkinson’s disease on chronic levodopa therapy. The management of LID is important as dyskinesia can be disabling and impair quality of life. Currently, there are limited treatment options for the medical management o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Vibhash D, Lyons, Kelly E, Pahwa, Rajesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905495/
https://www.ncbi.nlm.nih.gov/pubmed/29695911
http://dx.doi.org/10.2147/TCRM.S144481
Descripción
Sumario:Levodopa-induced dyskinesia (LID) is a common motor complication in patients with Parkinson’s disease on chronic levodopa therapy. The management of LID is important as dyskinesia can be disabling and impair quality of life. Currently, there are limited treatment options for the medical management of LID. Amantadine extended-release capsules (Gocovri™) is the first medication that received US Food and Drug Administration approval for the treatment of LID. The following is a review of the pharmacodynamics, efficacy and safety profile, and current state of treatment of amantadine for LID.

Ejemplares similares